You have free access to this content

Cancer

Cover image for Cancer

15 December 2003

Volume 98, Issue 12

Pages 2539–2742

  1. Original Articles

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma (pages 2539–2546)

      Ramachandran Prasad, Gary P. Boland, Angela Cramer, Elizabeth Anderson, W. Fiona Knox and Nigel J. Bundred

      Version of Record online: 3 NOV 2003 | DOI: 10.1002/cncr.11836

      The biologic effect of continuing hormone replacement therapy (HRT) after a diagnosis of breast carcinoma is unclear. The goal of the current study was to determine the short-term effect of HRT withdrawal on invasive breast carcinoma using biologic surrogate markers of tumor response.

    2. You have free access to this content
      Do we need HER-2/neu testing for all patients with primary breast carcinoma? (pages 2547–2553)

      Susanne Taucher, Margaretha Rudas, Robert M. Mader, Michael Gnant, Peter Dubsky, Thomas Bachleitner, Sebastian Roka, Florian Fitzal, Daniela Kandioler, Emanuel Sporn, Josef Friedl, Martina Mittlböck and Raimund Jakesz

      Version of Record online: 22 OCT 2003 | DOI: 10.1002/cncr.11828

      • original image

      In 923 patients with primary breast carcinoma, HER-2/neu status was correlated significantly with hormone receptor status and tumor grade. The assessment of HER-2/neu status may be considered unnecessary in patients with hormone-responsive and Grade 1/2 breast tumors.

    3. You have free access to this content
      Correlation of bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes (pages 2554–2559)

      Banu Arun, Gokhan Kilic, Charles Yen, Barbara Foster, Denise Yardley, Richard Gaynor and Raheela Ashfaq

      Version of Record online: 3 NOV 2003 | DOI: 10.1002/cncr.11853

      • original image
      • original image
      • original image
      • original image
      • original image

      In the current study, p53 and Bcl-2 expression in primary breast tumor tissue specimens and corresponding metastatic lymph node specimens was analyzed in 60 patients with breast carcinoma. p53 and Bcl-2 expression in primary tumor tissue specimens was found to be correlated with p53 and Bcl-2 expression in corresponding metastatic lymph node specimens. The predictive and prognostic significance of the expression of p53 and Bcl-2 in metastatic lymph nodes needs to be evaluated in larger prospective trials.

    4. Genitourinary Disease
      You have free access to this content
      Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma (pages 2560–2565)

      Kris K. Rasiah, Phillip D. Stricker, Anne-Maree Haynes, Warick Delprado, Jennifer J. Turner, David Golovsky, Phillip C. Brenner, Raji Kooner, Gordon F. O'Neill, John J. Grygiel, Robert L. Sutherland and Susan M. Henshall

      Version of Record online: 3 NOV 2003 | DOI: 10.1002/cncr.11850

      • original image
      • original image

      Primary Gleason pattern was a clinically relevant predictor of outcome in patients with Gleason score 7 prostate carcinoma undergoing radical prostatectomy.

    5. You have free access to this content
      Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma : A stratification tool for prospective clinical trials (pages 2566–2575)

      Bradley C. Leibovich, Ken-ryu Han, Matthew H. T. Bui, Allan J. Pantuck, Frederick J. Dorey, Robert A. Figlin and Arie Belldegrun

      Version of Record online: 5 NOV 2003 | DOI: 10.1002/cncr.11851

      • original image
      • original image
      • original image

      There have been recent studies suggesting that nephrectomy and immunotherapy can improve survival of patients with metastatic renal cell carcinoma (RCC). Multivariate analysis of patients with metastatic RCC who were treated with nephrectomy and high-dose interleukin-2 indicated that regional lymph node status, constitutional symptoms, location of metastases, sarcomatoid histology, and thyroid-stimulating hormone levels were associated with survival. The authors present a scoring algorithm based on these features that can be used to predict survival in patients who present with metastatic RCC and to stratify such patients for prospective clinical trials.

    6. You have free access to this content
      Prostate carcinoma tissue proteomics for biomarker discovery (pages 2576–2582)

      Yaxin Zheng, Ye Xu, Bin Ye, Junyi Lei, Michael H. Weinstein, Michael P. O'Leary, Jerome P. Richie, Samuel C. Mok and Brian C.-S. Liu

      Version of Record online: 3 NOV 2003 | DOI: 10.1002/cncr.11849

      • original image
      • original image
      • original image
      • original image

      Prostate-specific antigen (PSA) levels alone for screening for prostate carcinoma was compromised by the variations in the amount of PSA produced by benign prostatic tissue specimens. Using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, the authors identified a protein with an average mass-to-charge ratio (m/Z) of 24,782.56 ± 107.27 that was correlated with the presence of prostate carcinoma. In addition, this protein was not expressed in any of the 12 benign prostatic hyperplasia specimens that were assayed. Therefore, this protein may be useful a marker for prostate carcinoma.

    7. You have free access to this content
      Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy (pages 2583–2591)

      Masood A. Khan, Patrick C. Walsh, M. Craig Miller, Wesley D. Bales, Jonathan I. Epstein, Leslie A. Mangold, Alan W. Partin and Robert W. Veltri

      Version of Record online: 20 OCT 2003 | DOI: 10.1002/cncr.11852

      • original image
      • original image
      • original image
      • original image

      Quantitative nuclear grade (QNG) solutions derived from sets of nuclear morphometric descriptors of size, shape, DNA content, and chromatin texture independently predicted which men with biochemical recurrence after radical prostatectomy were likely to experience more rapid progression to distant metastasis and/or death. Therefore, the QNG biomarker may allow a more reliable prediction at the time of surgery of which patients may benefit from immediate adjuvant therapy.

    8. You have free access to this content
      A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma : Cancer and Leukemia Group B 99813 (pages 2592–2598)

      William K. Oh, Susan Halabi, W. Kevin Kelly, Cary Werner, Paul A. Godley, Nicholas J. Vogelzang, Eric J. Small and for the Cancer and Leukemia Group B

      Version of Record online: 10 NOV 2003 | DOI: 10.1002/cncr.11829

      • original image

      In a Phase II multicenter, cooperative group trial of men with hormone-refractory prostate carcinoma, estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support resulted in a ≥ 50% decline in prostate-specific antigen in 68% of patients, as well as measurable responses in 52% of patients.

    9. Gynecologic Oncology
      You have free access to this content
      Prophylactic oophorectomy : A morphologic and immunohistochemical study (pages 2599–2606)

      Peter W. Schlosshauer, Carmel J. Cohen, Frederique Penault-Llorca, Carlos R. Miranda, Yves-Jean Bignon, Jacques Dauplat and Liane Deligdisch

      Version of Record online: 5 NOV 2003 | DOI: 10.1002/cncr.11848

      • original image
      • original image
      • original image
      • original image

      Prophylactically removed ovaries were compared with normal ovaries and papillary serous ovarian carcinomas regarding morphologic features and expression of neoplasia-associated markers. Findings suggest the existence of preneoplastic changes in ovarian surface epithelium.

    10. You have free access to this content
      Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies (pages 2607–2623)

      Isabelle H. Roland, Wan-Lin Yang, Dong-Hua Yang, Mary B. Daly, Robert F. Ozols, Thomas C. Hamilton, Henry T. Lynch, Andrew K. Godwin and Xiang-Xi Xu

      Version of Record online: 5 NOV 2003 | DOI: 10.1002/cncr.11847

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      An increase in cyclooxygenase-2 staining was found to be correlated with the loss of epithelial basement membrane in ovarian surface epithelia from prophylactic oophorectomies.

    11. You have free access to this content
      The value of routine follow-up in patients treated for carcinoma of the vulva (pages 2624–2629)

      Maaike H. M. Oonk, Joanne A. de Hullu, Harry Hollema, Marian J. E. Mourits, Elisabeth Pras, Anke N. M. Wymenga and Ate G. J. van der Zee

      Version of Record online: 14 OCT 2003 | DOI: 10.1002/cncr.11837

      • original image

      Follow-up in patients with vulvar carcinoma has been routine for many years, although to the authors' knowledge its value has never been demonstrated. The data from the current study indicate that routinely scheduled follow-up meetings for patients with carcinoma of the vulva result in the detection of smaller recurrences in a substantial proportion of patients compared with self-reported recurrences.

    12. Hematologic Malignancies
      You have free access to this content
      Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission : The prognostic value of β2-microglobulin and the tumor score (pages 2630–2635)

      Issa F. Khouri, Rima M. Saliba, Grace-Julia Okoroji, Sandra A. Acholonu and Richard E. Champlin

      Version of Record online: 29 OCT 2003 | DOI: 10.1002/cncr.11838

      • original image
      • original image

      Mantle cell lymphoma (MCL) is a discrete entity characterized by generalized lymphadenopathy with frequent involvement of the bone marrow, spleen, and gastrointestinal tract. The reported outcome in patients with MCL treated with conventional therapy alone has been poor. In 1994, the authors began to examine the efficacy of high-dose cyclophosphamide and total body irradiation followed by autologous stem cell transplantation (ASCT) in patients with MCL in first disease remission. The current study was conducted to analyze the long-term results of ASCT in patients with diffuse MCL in first disease remission.

    13. You have free access to this content
      Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase : Comparison with historic data (pages 2636–2642)

      Hagop M. Kantarjian, Susan O'Brien, Jorge Cortes, Francis J. Giles, Mary Beth Rios, Jianqin Shan, Stefan Faderl, Guillermo Garcia-Manero, Alessandra Ferrajoli, Srdan Verstovsek, William Wierda, Michael Keating and Moshe Talpaz

      Version of Record online: 3 NOV 2003 | DOI: 10.1002/cncr.11831

      • original image
      • original image

      The authors compared the outcome of 187 patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase with a historic group of 650 patients receiving interferon-alpha regimens (1982–1997). Multivariate analysis indicated a significant survival advantage for imatinib therapy.

  2. Original Article

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. Disease Site

      Hematologic Malignancies
      You have free access to this content
      Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood (pages 2643–2650)

      E. Anders Kolb, Qiulu Pan, Marc Ladanyi and Peter G. Steinherz

      Version of Record online: 6 NOV 2003 | DOI: 10.1002/cncr.11895

      • original image

      Imatinib mesylate currently is included in the treatment of adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML). However, few data are available regarding its use in pediatric patients with CML. In the current study, the authors examined the use of imatinib mesylate in the treatment of pediatric patients with CML and evaluated response using cytogenetics, fluorescent in situ hybridization, and reverse transcriptase-polymerase chain reaction.

  3. Original Articles

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. Disease Site

      Hematologic Malignancies
      You have free access to this content
      Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients : Comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage (pages 2651–2656)

      Keun-Wook Lee, Dae-Young Kim, Tak Yun, Dong-Wan Kim, Tae-You Kim, Sung-Soo Yoon, Dae Seog Heo, Yung-Jue Bang, Seonyang Park, Byoung Kook Kim and Noe Kyeong Kim

      Version of Record online: 29 OCT 2003 | DOI: 10.1002/cncr.11846

      • original image
      • original image

      Elderly patients with diffuse large B-cell lymphoma who received doxorubicin at dose intensities ≥ 10 mg/m2 per week had treatment outcomes comparable to those of young patients. Although a reduction in doxorubicin dose was unavoidable for 36% of the elderly patients in the current series, 29% of elderly patients experienced inappropriate dose reductions, which stemmed from physician bias in response to patient age; this bias resulted in poor treatment outcomes.

  4. Original Article

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. Disease Site

      Hematologic Malignancies
      You have free access to this content
      Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia (pages 2657–2663)

      Susan M. O'Brien, Hagop M. Kantarjian, Deborah A. Thomas, Jorge Cortes, Francis J. Giles, William G. Wierda, Charles A. Koller, Alessandra Ferrajoli, Mary Browning, Susan Lerner, Maher Albitar and Michael J. Keating

      Version of Record online: 6 NOV 2003 | DOI: 10.1002/cncr.11871

      • original image
      • original image

      The authors investigated the efficacy and safety of the humanized anti-CD52 monoclonal antibody, alemtuzumab, in patients with B-cell chronic lymphocytic leukemia and residual disease. Alemtuzumab produced significant responses in patients with residual disease after chemotherapy. Bone marrow disease was eradicated more frequently than lymph node disease, and molecular disease remissions were achieved.

  5. Original Articles

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. Disease Site

      Hepatobiliary Disease
      You have free access to this content
      Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules (pages 2664–2670)

      Julien Taïeb, Luminita Bonyhay, Lamia Golli, Michel Ducreux, Emmanuel Boleslawski, Jean-Marie Tigaud, Thierry de Baere, Touraj Mansourbakht, Marie Anna Delgado, Laureut Hannoun, Thierry Poynard and Valerie Boige

      Version of Record online: 10 NOV 2003 | DOI: 10.1002/cncr.11869

      • original image

      Gemcitabine plus oxaliplatin is tolerated relatively well and has a certain efficacy in patients with advanced hepatocellular carcinoma.

    2. You have free access to this content
      The des-γ-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma (pages 2671–2677)

      Sakae Nagaoka, Hiroshi Yatsuhashi, Hisayuki Hamada, Koji Yano, Takehiro Matsumoto, Manabu Daikoku, Kokichi Arisawa, Hiromi Ishibashi, Michiaki Koga, Michio Sata and Michitami Yano

      Version of Record online: 5 NOV 2003 | DOI: 10.1002/cncr.11839

      • original image
      • original image
      • original image

      The des-γ-carboxy prothrombin (CDP) Index is a new prognostic indicator in patients with hepatocellular carcinoma who had small, solitary tumors and a child A classification at the time of diagnosis.

    3. Neuro-Oncology
      You have free access to this content
      Salvage therapy in patients with glioblastoma : Is there any benefit? (pages 2678–2686)

      Peter Hau, Ulrike Baumgart, Katharina Pfeifer, Anne Bock, Tanya Jauch, Jörg Dietrich, Klaus Fabel, Oliver Grauer, Caecilia Wismeth, Monika Klinkhammer-Schalke, Michael Allgäuer, Gerhard Schuierer, Horst Koch, Juergen Schlaier, Winfried Ulrich, Alexander Brawanski, Ulrich Bogdahn and Andreas Steinbrecher

      Version of Record online: 13 NOV 2003 | DOI: 10.1002/cncr.11845

      • original image

      The current article addressed reintervention strategies for patients with glioblastoma. The authors demonstrated that it is possible to select patients with glioblastoma who are good candidates for an aggressive reintervention strategy at the time of first disease recurrence. They also showed that these patients improved their overall survival without compromising their quality of life.

    4. Sarcoma
      You have free access to this content
      Complications in long-term survivors of Ewing sarcoma (pages 2687–2692)

      Bruno Fuchs, Richard G. Valenzuela, Carrie Inwards, Franklin H. Sim and Michael G. Rock

      Version of Record online: 3 NOV 2003 | DOI: 10.1002/cncr.11891

      • original image
      • original image
      • original image

      Multimodality treatment has been reported to dramatically improve the outcome of patients with Ewing sarcoma. However, little information concerning treatment-related complications in patients who are long-term survivors is available. In the current study, 41 patients with Ewing sarcoma who survived the disease by at least 20 years were included and, in a retrospective analysis, all complications related to the multimodality treatment of Ewing sarcoma were assessed.

  6. Original Article

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. Disease Site

      Sarcoma
      You have free access to this content
      A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas (pages 2693–2699)

      Jonathan C. Trent, Jennifer Beach, Michael A. Burgess, Nicholas Papadopolous, Lei L. Chen, Robert S. Benjamin and Shreyaskumar R. Patel

      Version of Record online: 6 NOV 2003 | DOI: 10.1002/cncr.11875

      • original image
      • original image
      • original image
      • original image
      • original image

      Soft tissue sarcomas (STSs) are a heterogeneous group of diseases comprised of numerous histologic subtypes that display a wide range of natural histories and responses to systemic therapies. For example, gastrointestinal stromal tumors (GISTs) usually are refractory to the chemotherapeutic agents doxorubicin and ifosfamide, whereas leiomyosarcomas of the extremities, uterus, and retroperitoneum are sensitive to these agents. An oral alkylating agent derived from imidazotetrazine, temozolomide, has been reported to exhibit broad-spectrum antitumor activity against murine tumors. In the current study, the authors conducted a two-arm Phase II study of temozolomide to determine its efficacy and toxicity in patients with STSs who had received, had refused, or were not eligible for standard chemotherapy with doxorubicin and ifosfamide (Arm 1) and in patients with GISTs (Arm 2).

  7. Original Articles

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. Disease Site

      Sarcoma
      You have free access to this content
      Should molecular testing be required for diagnosing synovial sarcoma? : A prospective study of 204 cases (pages 2700–2707)

      Jean-Michel Coindre, Manuela Pelmus, Isabelle Hostein, Catherine Lussan, Binh N. Bui and Louis Guillou

      Version of Record online: 23 OCT 2003 | DOI: 10.1002/cncr.11840

      • original image
      • original image
      • original image

      To evaluate the utility of molecular testing for the diagnosis of synovial sarcoma (SS), the detection of SYT-SSX transcripts was systematically performed using the real-time polymerase chain reaction on 204 fixed, embedded tissue specimens of possible synovial sarcomas. Molecular testing proved to be very helpful or necessary when the diagnosis of SS was suspected, but was challenged by other tumor types, mainly other spindle cell sarcomas, round cell sarcomas, carcinomas, myoepitheliomas, and epithelioid fibrosarcomas.

    2. Skin
      You have free access to this content
      Superficial radiotherapy for patients with basal cell carcinoma : Recurrence rates, histologic subtypes, and expression of p53 and Bcl-2 (pages 2708–2714)

      Beate Zagrodnik, Werner Kempf, Burkhardt Seifert, Beatrix Müller, Günter Burg, Mirjana Urosevic and Reinhard Dummer

      Version of Record online: 29 OCT 2003 | DOI: 10.1002/cncr.11798

      • original image
      • original image
      • original image
      • original image

      The current retrospective study demonstrates that basal cell carcinomas (BCCs) of the sclerosing subtype are a risk factor for recurrence after patients receive radiotherapy. Expression of p53 and Bcl-2 is associated with the aggressiveness in BCC subtypes.

    3. Discipline

      Pediatric Oncology
      You have free access to this content
      Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia (pages 2715–2722)

      Susana C. Raimondi, Yinmei Zhou, Susan Mathew, Sheila A. Shurtleff, John T. Sandlund, Gaston K. Rivera, Frederick G. Behm and Ching-Hon Pui

      Version of Record online: 5 NOV 2003 | DOI: 10.1002/cncr.11841

      • original image
      • original image
      • original image

      The authors performed a retrospective analysis of children with acute lymphoblastic leukemia and hypodiploidy treated at a single institution. They corroborated findings that hypodiploidy with fewer than 45 chromosomes is a high-risk feature and suggested that patients in this category are reasonable candidates for allogeneic stem cell transplantation. In contrast, hypodiploidy with 45 chromosomes was associated with a good outcome.

    4. Psychological Oncology
      You have free access to this content
      Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation : A randomized controlled trial (pages 2723–2729)

      Barrie R. Cassileth, Andrew J. Vickers and Lucanne A. Magill

      Version of Record online: 6 NOV 2003 | DOI: 10.1002/cncr.11842

      • original image

      Patients undergoing high-dose therapy with autologous stem cell transplantation have been reported to experience significant psychological distress during the long inpatient stay. In a randomized trial, music therapy provided by trained therapists lowered mood disturbance compared with standard care.

    5. Translational Research
      You have free access to this content
      Free interferon-α/β receptors in the circulation of patients with adenocarcinoma (pages 2730–2733)

      Julian L. Ambrus Sr., Wlodzimierz Dembinski, Julian L. Ambrus Jr., Donald E. Sykes, Selina Akhter, Mahmoud N. Kulaylat, Abul Islam and Kailash C. Chadha

      Version of Record online: 20 OCT 2003 | DOI: 10.1002/cncr.11843

      • original image

      In 91 patients with neoplastic disease, significantly increased free circulating interferon-α/β type 1 receptors were found compared with 25 healthy individuals. The highest levels were noted in patients with various types of adenocarcinomas.

  8. Book Reviews

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. You have free access to this content
      Toxicological carcinogenesis : David B. Clayson, Ph.D. (pages 2734–2735)

      John H. Weisburger

      Version of Record online: 10 NOV 2003 | DOI: 10.1002/cncr.11864

  9. Correspondence

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. You have free access to this content
    2. You have free access to this content
      Author reply (page 2737)

      Lisa A. Newman

      Version of Record online: 7 NOV 2003 | DOI: 10.1002/cncr.11834

    3. You have free access to this content
      Mediastinal irradiation in patients with esophageal carcinoma after heart transplantation (pages 2737–2738)

      Youlia Kirova, Cristelle Locher and Jean-Leon Lagrange

      Version of Record online: 6 NOV 2003 | DOI: 10.1002/cncr.11896

    4. You have free access to this content
      Hospitalization of an oncology patient suspected of having severe acute respiratory syndrome : A setup for an infection control quagmire at a comprehensive cancer center (pages 2738–2739)

      Amar Safdar, Roy F. Chemaly, Cheryl A. Perego, Virginia R. Gonzalez B.S., Kenneth V. Rolston, Issam I. Raad, Jeffrey J. Tarrand and David L. Callender

      Version of Record online: 17 NOV 2003 | DOI: 10.1002/cncr.11862

  10. Communication

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. You have free access to this content
      Classification of isolated tumor cells : Clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual (pages 2740–2741)

      S. Eva Singletary, Frederick L. Greene and Leslie H. Sobin

      Version of Record online: 5 NOV 2003 | DOI: 10.1002/cncr.11865

      In May 2002, the 6th edition of the American Joint Committee on Cancer staging manual was published. This new staging system was officially adopted for use in tumor registries in January 2003. The changes adopted for the chapter concerning breast carcinoma were the result of recommendations made by a task force charged with proposing changes that reflected published clinical data and current clinical consensus.

  11. Erratum

    1. Top of page
    2. Original Articles
    3. Original Article
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Original Article
    8. Original Articles
    9. Book Reviews
    10. Correspondence
    11. Communication
    12. Erratum
    1. You have free access to this content

SEARCH

SEARCH BY CITATION